Transarterial chemoembolization and hepatic arterial infusion
chemotherapy are recommended for the treatment in patients with intermediate stage of
hepatocellular carcinoma. Impaired liver function was sometime observed in patients with
hepatocellular carcinoma after transarterial chemoembolization or hepatic arterial infusion
chemotherapy. However, what kinds of factors deeply influence in impaired liver function are not clear. A retrospective study was performed to evaluate the risk factors of impaired liver function in
cisplatin-naïve patients treated with these
therapies using
cisplatin. Prior to and 2 months after these
therapies, we analyzed the liver function by Child-Pugh score in these patients. For assessing the severity of
chemotherapy-induced
nausea and
vomiting, we utilized the Common Terminology Criteria for Adverse Events ver. 4.0. In
hepatocellular carcinoma patients received these
therapies using
cisplatin, the
cancer stage and treatment without neurokinin-1 (NK1) antagonist were found to be independent risk factors of the impaired liver function. The treatment with NK1 antagonist was effective in reducing
chemotherapy-induced
nausea and
vomiting and patients treated with NK1 antagonist kept their liver functions after
cisplatin-used these
therapies. The treatment with NK1 antagonist was effective in
chemotherapy-induced
nausea and
vomiting and prevented the impaired liver function associated with
cisplatin-used these
therapies in
hepatocellular carcinoma patients.